Universal platform for targeting therapies to treat neurological diseases
AssigneesThe Medical College of Wisconsin, Inc., Wisconsin Alumni Research Foundation
InventorsJoseph T. Barbieri, Chen Chen, Amanda Przedpelski, Eric A. Johnson, Sabine Pellett
Life of this patent
Estimating the term…
Abstract
The present invention provides a universal delivery platform of functional, heterologous compounds to specific cells using toxins modified to include a heterologous compound. In one embodiment, the toxin is an AB5 toxin. In one embodiment, the AB5 toxin is a heat-labile enterotoxin from E. coli (LT), including LTI, LTII, LTIIa, LTIIb, LTIIc and other recombinant forms of LT. Methods of use are also provided.
Claims17
A delivery platform comprising a toxin modified to incorporate a heterologous compound.
A method of treating botulism comprising administering a delivery platform comprising an AB5 toxin modified to incorporate β-lactamase to a subject in need thereof, wherein the botulism is treated.
A method of treating Parkinson's Disease comprising administering a delivery platform comprising a toxin modified to incorporate a heterologous compound to a subject in need thereof, wherein the heterologous compound comprises a neuroprotective agent, and wherein the Parkinson's Disease is treated.
A method of treating Cystic Fibrosis (CF) comprising administering a delivery platform comprising a toxin modified to incorporate a heterologous compound to a subject in need thereof, wherein the heterologous compound comprises a CFTR polypeptide, and wherein the CF is treated.
Dependencies are inferred from the claim text.